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Identity 
Other names: DKFZp434K0220; VR1 
HGNC (Hugo): TRPV1 
Location: 17p13.2 
Local order: Colocalized with another transient 
receptor potential channel gene (TRPV3). 
DNA/RNA 
Description 
TRPV1 gene consists of 17 exons and 17 introns  
including a coding region and a 5' and a 3' non-coding 
region. 
Transcription 
There are four transcript variants encoding the same 
protein, but with different segments in the 5' UTR 
(var.1, var.2, var.3, var.4) and one alternative splice 
variant lacking exon 7 (TRPV1b). TRPV1 gene 
transcription was demonstrated in different cells and 






Schematic representation of human TRPV1 gene and neighbouring family gene. 
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Genomic structure of human TRPV1. In gene the exon number and relative length in bp are shown. In cDNA, the coding region is 
shown by open bars. The non-traslated regions are shown by black filled bars. The different 5' UTR TRPV1 splice variants with relative 5' 
UTR length are described in table. The TRPV1 splice variant (TRPV1b) is described in table. Hyperlink to FASTA nucleotide sequences 
of all TRPV1 cDNAs are inserted. 
 
Schematic representation of TRPV1 protein. Double broken line is representative of cellular membrane, transmembrane domains are 
numbered. Red spot indicates the position of the three ankyrin repeat domains and a representative image of the structural ankyrin 
repeat unit containing two antiparallel helices and a beta-hairpin, with repeats that are stacked in a superhelical arrangement is shows in 
black box (from NCBI Conserved Domains), N and C (-terminal domains). SP (signal peptide region), ANK (ankyrin regions, red box), TM 
(trasmembrane domain, grey box), ED (extracellular domain, blue box), CD (cytoplasmatic domain, orange box), PFD (pore forming 
domain, green box). An association domain (AD) in 685-713 region has been found necessary for self-association. 
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Protein 
Description 
The canonical form comprises 839 aa (MW~96 kDa) 
and is composed of six transmembrane spanning 
domains and a pore forming region between 
transmembrane domains 5 and 6. The N-terminal and 
C-terminal tails are in cytoplasmatic side. Three N 
terminal ankyrin (ANK) repeats are present in N-
terminal tail. The variant form TRPV1b is identical to 
TRPV1 except for the partial deletion of the third 
ankyrin repeat domain and adjoining polypeptide 
sequence. Aminoacid modifications has been found 
(according to Swiss-Prot) in different residues (Table 
1). The N-terminal intracellular domain appears to play 
a pivotal role in intracellular activation of TRPV1, in 
fact, by mutagenesis analysis a loss of sensitivity to 
capsaicin has been found related to residue Tyr-511 
(Gavva et al., 2004). Modification of a single N-
terminal cysteine altered activation of TRPV1 by 
pungent compounds ranging from onions to garlic 
(Salazar et al., 2008). The N-terminal intracellular 
domain also interacts with adjacent modulatory 
proteins and with the C-terminal intracellular domain. 
In the closed state, the N-terminal domain is likely 
exposed to the binding of ATP and a C-terminal region 
residues interact with PIP-2, facilitating channel 
activation. In contrast, a desensitized state may be 
promoted through the interaction of the N- and C-
terminal domains through modulatory action involving 
calcium-calmodulin interacting regions. Moreover, the 
ankyrin repeat domains residing within the N-terminal 
intracellular domain forming a region of three repeats 
spanning amino acids participating in protein-protein 
(subunit) interactions (Bork, 1993). The presence of 
concave binding surfaces for ATP within the ANK 
regions suggest a role of ANKs in modulating channel 
activation and function (Lishko et al., 2007). 
 











Table 1. Aminoacid number and type of putative 
modification in TRPV1 protein. 
Expression 
TRPV1 has also been found in different brain region, 
such as in dopaminergic neurones of the substantia 
nigra, hippocampal pyramidal neurones, hypothalamic 
neurones, neurones in the locus coeruleus, and in 
various layers of the cortex as in small to medium 
diameter primary afferent fibres, In non-neuronal cel s 
TRPV1 has been found in keratinocytes, bladder 
urothelium, smooth muscle, liver, polymorphonuclear 
granulocytes, pancreatic beta-cells, endothelial cells, 
lymphocytes, thymocytes and macrophages. Moreover 
by expression profile studies more cells and tissue has 
been analyzed for TRPV1 expression. 
Localisation 
TRPV1 is expressed in discrete spots in the plasma 
membrane and cytosol of different cell types (e.g. 
urothelial cells). Moreover, dorsal root ganglion (DRG) 
neurons express ectopic but functional TRPV1 
channels in the endoplasmic reticulum (ER) 
(TRPV1(ER)). 
Function 
TRPV1 agonists. TRPV1 is a non-selective cation 
channel, belonging to the superfamily of TRP channels. 
TRPV1 agonists are of exogenous and endogenous 
origins. Exogenous agonist are of natural, semi-
synthetic and synthetic origin. The natural compounds 
include dietary derived compounds as: capsaicinoids, 
capsinoids, piperine, allicin, alliin, eugenol and 
gingerol or non dietary plant compounds as 
resiniferatoxin, ∆9-tetrahydrocannabinol, cannabidiol 
and venom from animal origins (Pertwee, 2005; Vriens 
et al., 2009). Moreover, other environmental irritants as 
well as noxious heat (> 43-45 °C) has been found to ac  
as TRPV1 agonist. The existence of endogenous 
vanilloid agonists, a class of compounds referred to as 
endovanilloids, as TRPV1 channels modulators as been
also investigated. TRPV1 has been found to be 
activated by biogenic amines like N-
arachidonylethanolamine (AEA, anandamide), N-
arachidonoyldopamine (NADA), N-
oleoylethanolamine (OLEA), N-arachidonolylserine, 
and various N-acyltaurines and N-acylsalsolinols. 
Various lipids from the fatty acid pool have also been 
identified as TRPV1 activators, as inflammatory 
compounds such as bradykinin, products of the 
lipoxygenases (12-HPETE and leukotriene B4, 5(S)-
HPETE (hydroperoxyeicosatetranoic acid) and/or 
leukotriene B4) (Van Der Stelt and Di Marzo, 2004). 
Also nerve growth factor (NGF), an inflammatory 
mediator is known to activate/sensitize TRPV1 through 
the TrkA receptor, act primarily through 
phosphoinositide-3- kinase (PI3K) and mitogen 
activated protein kinase (MAPK) signaling pathways 
(Chuang et al., 2001).  
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TRPV1 antagonists. Natural TRPV1 antagonists are 
actually restricted to two plant derived compounds, the 
thapsigargin that is the irritant principle of Thapsia 
garganica L. and yohimbine, an indole alkaloid from 
the tree Corynanthe yohimbe K. The endogenous 
TRPV1 antagonists discovery up to now are 
dynorphins, adenosine, various dietary omega-3 fatty 
acids like eicosapentaenoic and linolenic acids, the
endogenous fatty acid amide hydrolase (FAAH) and 
different polyamines as putrescine, spermidine, and 
spermine permeate. The most active non-natural 
compound that act as TRPV1 antagonist are 
capsazepine and 5-iodoRTX. 
Ligand-binding site. By comparative analysis of the 
primary structure of theTRPV1 and by mutagenesis 
studies has been revealed a critical role for Tyr511 and 
Ser512 (between the second intracellular loop and 
TM3), confirming that the vanilloid binding site is 
located intracellulary, moreover a third critical residue 
in the putative TM4 segment (Leu547) was indicated as 
relevant in ligand-binding. 
The effect of extracellular protons (as Ca2+), acts 
primarily by increasing channel opening, rather than 
interacting directly with the vanilloid binding site. 
Related TRPV1 intracellular signaling 
pathways 
EGFR (epidermal growth factor receptor). TRPV1 
has been found to down-regulate epidermal growth 
factor receptor (EGFR) expression. Interaction of 
TRPV1 terminal cytosolic domain with EGFR induces 
EGFR ubiquitination and degradation. Moreover, by 
transfection of TRPV1 in HEK293 cells a decreased 
EGFR protein expression was observed (Bode et al., 
2009). 
Fas/CD95. Activation of TRPV1 with capsaicin, in 
low-grade urothelial cancer cells, induced a TRPV1-
dependent G0/G1 cell cycle arrest and apoptosis by 
inducing transcription of pro-apoptotic genes 
Fas/CD95, Bcl-2 and caspases, and by activation of the 
DNA damage response pathway. Moreover, CPS 
stimulation induced a TRPV1-dependent redistribution 
and its clustering with Fas/CD95. In addition, an 
involvement of capsaicin in activation of the ATM 
kinase/p53 pathways was found (Amantini et al., 2009). 
PKA (protein kinase A). TRPV1 are found 
phosphorylated by PKA in the amino terminus Ser116 
and Thr370 and involved in desensitisation while 
phosphorylation of Ser116 by PKA inhibits 
dephosphorylation of TRPV1 caused by capsaicin 
exposure (Mohapatra and Nau, 2003). 
PKC (protein kinase C). Several inflammatory 
mediators, like ATP, bradykinin, prostaglandins and 
trypsin or tryptase activated Gq coupled receptors and 
induced PKC-dependent phosphorylation of TRPV1 
(Moriyama et al., 2003).  
PKC dependent phosphorylation of TRPV1 potentiates 
capsaicin- or proton-evoked responses and reduces 
temperature 'threshold' for TRPV1 activation. Direct 
phosphorylation of TRPV1 by PKC has been located at 
Ser502 and Ser800 (Bhave et al., 2003). 
IGF-I (insulin growth factor I). Insulin and IGF-I 
increase translocation of TRPV1 to the plasma 
membrane via activation of IGF receptors, which, in 
turn, induced PI(3) kinase and PKC activation (Van 
Buren et al., 2005). 
CdK5 (cyclin-dependent kinase 5). CdK5 can directly 
phosphorylate Thr407 in TRPV1, while inhibition of 
CdK5 activity decreases TRPV1 function and Ca2+ 
influx (Pareek et al., 2007). 
Homology 
86% identity with Mus musculus TRPV1, 85% with 




Bone cancer leads to osteoclast activation, which 
promotes acidosis and consequently TRPV1 activation 
in sensory fibers. The correlation between TRPV1 
activation and bone cancer pain was demonstrated by 
the evaluation of the RTX analgesic effects of 
pharmacological blockade of TRPV1. So, TRPV1 
activation plays a critical role in the generation of bone 
cancer pain, and bone cancer increases TRPV1 
expression within distinct subpopulation of DRG 
neurons (Niiyama et al., 2007). 
Skin cancer 
Oncogenesis 
TRPV1 is highly and specifically expressed in both 
premalignant (leukoplasia) and low-grade papillary 
skin carcinoma, whereas its expression is substantially 
absent in invasive carcinoma. Recently, TRPV1 has 
been found to exhibit tumor suppressive activity on 
skin carcinogenesis in mice because of its ability to 
down-regulate epidermal growth factor receptor 
(EGFR) expression; conversely, loss of TRPV1 
expression resulted in marked increase in papilloma 
development. TRPV1 by interacting with EGFR 
through its terminal cytosolic domain, facilitates Cbl-
mediated EGFR ubiquitination and subsequently its 
degradation via the lysosomal pathway. In addition, 
ectopic TRPV1 expression in HEK293 cells resulted in 
decreased EGFR protein expression, and higher EGFR 
levels were observed in the skin of TRPV1 deficient 
mice (TRPV1-/-) as compared to wild-type control 
animals (Marincsák et al., 2009; Hwang et al., 2010). 
Urothelial cancer 
Oncogenesis 
Changes in the TRPV1 expression occur during the 
development of human urothelial cancer. Thus, 
transitional cell carcinoma (TCC) show a progressive 
decrease in TRPV1 expression as the tumor stage 
increases. Treatment of low-grade RT4 urothelial 
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cancer cells with a specific TRPV1 agonist, capsaicin 
(CPS) induced a TRPV1-dependent G0/G1 cell cycle 
arrest and apoptosis. These events were associated with 
the transcription of pro-apoptotic genes including 
Fas/CD95, Bcl-2 and caspases, and with the activation 
of the DNA damage response pathway. Moreover, 
stimulation of TRPV1 by CPS significantly increased 
Fas/CD95 protein expression and more importantly 
induced a TRPV1-dependent redistribution and 
clustering of Fas/CD95 that co-localized with the 
vanilloid receptor, suggesting that Fas/CD95 ligand-
independent TRPV1-mediated Fas/CD95 clustering 
results in death-inducing signaling complex formation 
and triggering of apoptotic signaling through both the 
extrinsic and intrinsic mitochondrial-dependent 
pathways. Moreover, we found that CPS activates the 
ATM kinase involved in p53 Ser15, Ser20 and Ser392 
phosphorylation. ATM activation is involved in 
Fas/CD95 up-regulation and co-clustering with TRPV1 
as well as in urothelial cancer cell growth and 
apoptosis. Finally, the role of TRPV1 mRNA down-
regulation as a negative prognostic factor in patients 
with bladder cancer has been reported. By univariate 
analysis, cumulative survival curves calculated 
according to the Kaplan-Meier method for the canonic 
prognostic parameters such as tumor grade and high 
stage (pT4), lymph nodes and distant diagnosed 
metastasis, reached significance. Notably, the reduction 
of TRPV1 mRNA expression was associated with a 
shorter survival of urothelial cancer patients (P=0.008). 
On multivariate Cox regression analysis, TRPV1 
mRNA expression retained its significance as an 
independent risk factor, also in a subgroup of patients 
without diagnosed metastasis (M0). These findings 
may be particularly important in the stratification f 
urothelial cancer patients with higher risk of tumor 
progression for the choice of therapy options (Amantini 
et al., 2009; Kalogris et al., 2010). 
Glioblastoma 
Oncogenesis 
TRPV1 mRNA and protein expression was evidenced 
in normal astrocytes and glioma cells and tissues. Its 
expression inversely correlated with glioma grading, 
with a marked loss of TRPV1 expression in the 
majority of grade IV glioblastoma tissues. TRPV1 
activation by CPS induced apoptosis of U373MG 
glioma cells, and involved rise of Ca2+ influx, 
p38MAPK activation, mitochondrial permeability 
transmembrane pore opening and transmembrane 
potential dissipation, and caspase-3 activation 
(Amantini et al., 2007). 
Pancreatic cancer 
Oncogenesis 
Human pancreatic cancer, significantly expressed 
increased levels of TRPV1 mRNA and protein.  
 
However, resinferatoxin (RTX), a potent TRPV1 
agonist, induced apoptosis by targeting mitochondrial 
respiration, and decreased pancreatic cancer cell 




TRPV1 expression has been reported in human cervical 
cancer cell lines and tissues, and the endocannabinod 
anandamide (AEA) induced TRPV1-dependent tumor 
cell apoptosis. In addition, TRPV1 stimulation 
completely reverted the cannabidiol (CBD)-mediated 
inhibitory effect on human cervical cancer cell invasion 
by blocking CBD-induced increase of TIMP-1, a MMP 
inhibitor both at mRNA and protein levels, and 
ERK1/ERK2 and p38MAPK activation (Contassot et 
al., 2004a; Contassot et al., 2004b). 
Prostate cancer 
Oncogenesis 
A functional TRPV1 channel is expressed in human 
prostate cancer cells (PC3 and LNCaP) and in prostate 
hyperplasic tissue. Moreover, increased TRPV1 mRNA 
and protein expression was found in human prostate 
cancer tissues as compared to prostate hyperplastic and 
healthy donors, and this increase correlated with degree 
of malignancy. CPS induced a growth inhibition and 
apoptosis of PC3 prostate cancer cells, but in TRPV1-
independent manner, through ROS generation, 
mitochondrial inner transmembrane potential 
dissipation and caspase-3 activation. Moreover, CPSor 
the specific antagonist capsazepin inhibited tumor 
growth in vivo, in a xenograft human prostate PC3 
cancer model. By contrast, in androgen-responsive 
LNCaP prostate cancer cells, CPS was found to 
stimulate TRPV1-dependent cell proliferation. CPS 
effects were attributable to decreased ceramide levls 
and to activation of Akt/PKB and ERK pathways, and 
were associated with increased androgen receptor 
expression (Sanchez et al., 2005). 
Pheochromocytoma 
Oncogenesis 
TRPV1 expression has been also demonstrated on the 
plasma membrane of rat pheochromocytoma-derived 
PC12 cell line. PC12 stimulation by CPS resulted in 
TRPV1-dependent nitric oxide synthase (iNOS) 
expression. CPS exposure triggered Ca2+ influx, which 
in turn enhanced mitochondrial Ca2+ accumulation and 
promoted NO generation, events that have been 
associated with tumor progression (Qiao et al., 2004). 
Hepatocarcinoma 
Oncogenesis 
Hepatocarcinoma patients show high TRPV1 
expression that is associated with increased disease-free 
survival (Miao et al., 2008). 






Atlas Genet Cytogenet Oncol Haematol. 2011; 15(7)  593 
Digestive tract diseases 
Note 
TRPV1 sensitive sensory nerves are densely distributed 
in the gastrointestinal system, and one of the important 
roles of these nerves is the preservation of the tissues 
integrity from the exposed to aggressive compounds, 
such as protons and activated enzymes. Moreover, 
activation of TRPV1 either by endogenous or by 
exogenous agonists exerts hypotensive effects or 
protective effects against gastrointestinal injury. 
Therefore, TRPV1 is not only a prime target for the
pharmacological control of pain but also a useful target 
for drug development to treat various gastrointestinal 
diseases. The function of TRPV1 visceral sensitivity 
and hypersensitivity tends to be well established. It was 
shown the involvement of TRPV1 in the regulation of 
gastrointestinal motility and absorption, visceral 
sensation and visceral hypersensitivity (Holzer, 2010). 
Respiratory system diseases 
Note 
TRPV1 is expressed on vagal afferent C fibers in the 
lungs and may be activated by intense heat, acidic 
solutions, endocannabinoids, metabolites of 
arachidonic acid, capsaicin and ROS.The role of 
TRPV1 in respiratory system is correlated to date 
indicating that acidic solutions as other TRPV1-
inducing stimuli lead to C-fiber-mediated respiratoy 
reflexes and activation of these fibers leads to 
bronchoconstriction, mucus secretion, bradycardia and 
hypotension, in addition to cough and airway irritation 
(Taylor-Clark and Undem, 2006). 
Bladder diseases 
Note 
The role of TRPV1 in overactive (irritable) bladder 
disease has been shown in TRPV1 knockout mice 
where differences in their response to bladder injury 
when compared to their wild-type counterparts. TRPV1 
knockout mice didn't develop bladder overactivity 
during acute bladder inflammation, suggesting a role 
for TRPV1 in bladder inflammatory states. Moreover, 
in patients diagnosed with neurogenic detrusor 
overactivity (NDO), higher levels of TRPV1 
immunoreactivity in the urothelium and in the number 
of nerve fibers were found, compared to control 
(Apostolidis et al., 2005). 
Diseases of the basal ganglia 
Note 
TRPV1 plays a role in dopaminergic mechanisms 
associated with schizophrenia and Parkinson's disease. 
Exposure of mesencephalic dopaminergic neurons to 
the TRPV1 agonist capsaicin triggers cell death, while 
exposure to TRPV1 antagonists prevents these effects. 
In addition, schizophrenic patients tend to display 
reduced pain sensitivity and a diminished skin flare 
response to niacin, suggesting a defects in TRPV1-




TRPV1 is expressed in cardiac spinal sympathetic 
sensory fibers. During cardiac ischemia these fibers are 
essential for the sympathoexcitatory reflex, which s 
associated with increased blood pressure and chest 
pain. Acidosis TRPV1 activation and ischemia 
provides the organism with a mechanism, which relays 
painful information to the brain. Conversely, the 
release substance P (SP), neurokinin A (NKA) and 
CGRP by the nerve fiber itself has beneficial effects, 
which helping to reduce the effects of ischemia and 
acidosis. Some data indicated that spinal cord 
stimulation (SCS) used to improve peripheral blood 
flow in selected populations of patients with ischemia 
is mediated via VR-1 containing sensory fibers. 
Treatment of patients with the TRPV1 agonist RTX 
result in a SCS-induced vasodilation indicating a 
cardioprotective role for TRPV1 (Wu et al., 2006). 
Diabetes 
Note 
A fundamental role for insulin responsive TRPV1+ in 
pancreatic sensory neurons in controlling islet 
inflammation and insulin resistance function and 
diabetes pathoetiology has been demonstrated. Infact, 
eliminating these neurons in diabetes-prone NOD mice 
prevents insulitis and diabetes. In type 2 diabetes 
administration of capsaicin and RTX which desensitize 
TRPV1 result in improved glucose tolerance through 
enhancement of insulin secretion and decreased plasma 
insulin levels. So ablation of TRPV1-expressing 
neurons which innervate the pancreas through neonatal 
capsaicin treatment prevents the insulitis and pancreati  
beta-cell destruction that normally occurs in these 
animals (Gram et al., 2007; Razavi et al., 2006). 
Itch 
Note 
TRPV1 is expressed on the "pruriceptor subpopulation" 
of mechano insensitive fibers and the itch-selectiv 
sensory afferents respond to capsaicin.  
Itch sensation can be modulate by changing skin 
temperature and pH, to common TRPV1 activator 
stimuli. Therefore, TRPV1 may function as a 'central 
integrator' molecule in the itch pathway (Yosipovitch et 
al., 2005; Ghilardi et al., 2005). 
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